Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVENE: Preemptive Venetoclax in High-Risk Stage A CLL
2024-513718-37-00Phase 2Authorised
- Sponsor
- French Innovative Leukemia Organization
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by French Innovative Leukemia Organization. Planned start Aug 2024; status: authorised.
02
Drugs
venetoclax
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2024-513718-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513718-37-00.